Online Only Articles

Continuous high dosing of lenalidomide in relapsed, refractory or older newly diagnosed acute myeloid leukemia patients not suitable for other treatment options - results from a phase I study

Department of Internal Medicine III, University of Ulm
Department of Internal Medicine II, University Hospital Hamburg-Eppendorf, Hamburg
Department of Hematology, Oncology and Clinical Immunology, Heinrich-Heine University Düsseldorf
Department of Internal Medicine III, Hospital Braunschweig;Department of Hematology, Hemostasis, Oncology and Stem Cell Transplantation, Hannover Medical School, Germany
Department of Internal Medicine II, University Hospital Jena;Internal Medicine III, University Hospital of Bonn, Germany
Department of Internal Medicine III, University of Ulm
Department of Internal Medicine III, University of Ulm;National Center for Tumor Diseases, Heidelberg
Vol. 104 No. 2 (2019): February, 2019 https://doi.org/10.3324/haematol.2018.199794